Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 14,927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disorders Clear all
Recruiting Not applicable Interventional

Effects of Pomegranate Juice on Ulcerative Colitis

NCT07115862
View directory record Official record
Conditions
Ulcerative Colitis (Disorder)
Interventions
pomegranate juice -> habitual diet, habitual diet -> pomegranate juice
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

NCT03991962
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

NCT01482403
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Colonoscope Insertion Trial Protocol

NCT01324882
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy with Olympus Technically Improved Colonoscope, Control with standard colonoscope Olympus CF-H180
Device
Lead sponsor
UConn Health
Other
Eligibility
35 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 22, 2026, 2:57 PM EDT
Active, not recruiting Phase 2 Interventional

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

High-Resolution Measurements of Diet-Microbiome Interactions

NCT07856823
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome)
Interventions
Inulin, Low-fiber control breakfast shake, Atmo Gas-Sensing Capsule, CapScan Regional Fluid-Sampling Capsule
Dietary Supplement · Other · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Withdrawn No phase listed Observational

Metabiomics Colon Cancer Clinical Research Study

NCT02151123
View directory record Official record
Conditions
Colonic Neoplasms
Interventions
Not listed
Lead sponsor
Metabiomics Corp
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

NCT07644559
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Interventions
VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
27
States / cities
Los Angeles, California • Coral Springs, Florida • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy of Lidocaine Gel Enema After Endoscopic Hemorrhoid Band Ligation for Relief of Post Procedural Pain

NCT03797703
View directory record Official record
Conditions
Hemorrhoids
Interventions
Lidocaine Hydrochloride 2% gel enema
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 22, 2026, 2:57 PM EDT
Not yet recruiting Phase 4 Interventional

Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)

NCT07788742
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Potassium-Competitive Acid Blockers (PCABs)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Active, not recruiting Phase 2 Interventional

Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders

NCT03408886
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastrointestinal Disorder
Interventions
Vancomycin, MoviPrep, Full Spectrum Microbiota
Drug · Biological
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 22, 2026, 2:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

An Evaluation of a New Technique Utilizing a Biologic Glue and Tissue Patch to Seal the Cut Edge of the Pancreas Following Removal of the Tail of the Pancreas

NCT00889213
View directory record Official record
Conditions
Pancreatic Fistula, Distal Pancreatectomy Complications, Falciform Patch Pancreatic Closure, Fibrin Glue Pancreatic Closure
Interventions
Falciform patch and fibrin glue application, standard pancreatic closure
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

NCT02905188
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
GLYCAR T cells, Cytoxan, Fludarabine
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Upper Airway and Digestive Tract Tumors on the Immune System

NCT00001603
View directory record Official record
Conditions
Esophageal Neoplasm, Head and Neck Neoplasm, Laryngeal Neoplasm, Papilloma, Squamous Cell Carcinoma
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
Not listed
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 2:57 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures

NCT06579989
View directory record Official record
Conditions
Cough, Vocal Cord Atrophy, Vocal Cord Paresis, Vocal Cord Paralysis, Dysphagia, Dysphonia
Interventions
Ultrasound for cough, Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis, Ultrasound for dysphagia, Ultrasound for dysphonia
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational

Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease

NCT04531189
View directory record Official record
Conditions
Wilson Disease
Interventions
Not listed
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 22, 2026, 2:57 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

NCT02510560
View directory record Official record
Conditions
Premature Birth of Newborn, Intestinal Malabsorption
Interventions
NTRA-2112, Placebo
Drug
Lead sponsor
Elgan Pharma Ltd.
Industry
Eligibility
1 Day to 5 Days
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Greenville, North Carolina • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer

NCT00103324
View directory record Official record
Conditions
Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
Interventions
lapatinib ditosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 22, 2026, 2:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy

NCT00222079
View directory record Official record
Conditions
Gastro-esophageal Reflux
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
Douglas Trask
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional

Physical Activities by Technology Help (PATH)

NCT03212079
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Oral Cancer
Interventions
Mycoach Smart Text, MyCoach on Amazon Alexa
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational

Circulating Tumor Cells in Operative Blood

NCT02150746
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
Peripheral/Central Venous Blood Draw, Peritoneal Wash
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 22, 2026, 2:57 PM EDT
Recruiting Phase 1 Interventional

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

NCT07878988
View directory record Official record
Conditions
Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM, Colon Cancer
Interventions
LTZ-232
Drug
Lead sponsor
LTZ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 2:57 PM EDT